Piper Sandler analyst David Amsellem lowered the firm’s price target on Optinose (OPTN) to $1 from $3 and keeps an Overweight rating on ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Optinose (OPTN – Research Report), with a price target of $1.00. The company’s shares closed yesterday at $0.60 ...

The Piper Sandler (NYSE ... is going to be volatile but the market is backing this stock today. Analyst David Amsellem reiterated his overweight rating of Revance Therapeutics (NASDAQ:RVNC ...

ANI Pharmaceuticals (NASDAQ:ANIP) traded higher in the premarket trading on Friday after Piper Sandler launched ... company's portfolio mix. Analyst David Amsellem argued that Baudette, Minnesota ...

The Commodity Futures Trading Commission said it ordered Piper Sandler to pay a $2 million fine to settle charges against the company's introducing broker for failing to meet recordkeeping ...

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.

MINNEAPOLIS, September 03, 2024--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is excited to announce the hiring of David Hunker as managing director and global head of activist ...

Piper Sandler Companies (NYSE:PIPR) had its earnings report come in. The last time we covered them, we acknowledged that ECM and DCM spurts may be short-lived, which is what happened. However ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Myles Minter; Analyst; William Blair & Company, L.L.C. Joel Beatty; Analyst; Robert W. Baird & Co., Inc. Graig Suvannavejh; Analyst; Mizuho Securities USA Matt Kaplan ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...